## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.13 indicates fundamental undervaluation. Quality metrics strong (ROE 30%, ROA 14%). Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-3.8% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($88.17)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Incyte gains FDA Breakthrough designation for its candidate against essential thrombocythemia**
- Source: marketscreener.com | 20251208T155207 | Bullish | Relevance: 99%
-  Incyte announced that its experimental treatment, INCA033989, for essential thrombocythemia has received FDA Breakthrough Therapy designation. This designation aims to accelerate development, supported by Phase 1 data showing good tolerability and normalization of platelet counts, with enhanced responses at higher doses. Incyte plans to launch a registry program for patients resistant or intolerant to existing therapies in the first half of 2026.

**2. Incyte Names Veteran Biopharma Attorney as New General Counsel**
- Source: MyChesCo | 20251208T120826 | Bullish | Relevance: 99%
-  Incyte Corp. (Nasdaq: INCY) has appointed Richard Hoffman as executive vice president and general counsel, effective December 1. Hoffman brings over two decades of experience in the life sciences sector, having previously served as a partner in Goodwin's Life Sciences group. He will oversee Incyteâ€™s legal and compliance functions as the company expands its pipeline and global footprint.

**3. Incyte stock holds Market Perform rating at Citizens on CALR therapy lead**
- Source: Investing.com | 20251209T112451 | Bullish | Relevance: 99%
-  Citizens maintained its Market Perform rating on Incyte (NASDAQ:INCY) due to its first-mover advantage in CALR-mutant myeloproliferative neoplasms (MPNs) therapy with its '989 therapy. The company has seen significant momentum, with shares up 40% year-to-date, and positive revisions to earnings expectations from 13 analysts. Despite increasing competition, Incyte is considered the leader, though continued differentiation will be crucial.

**4. Incyte (NASDAQ:INCY) Trading Down 6.6% - Should You Sell?**
- Source: MarketBeat | 20251208T190851 | Neutral | Relevance: 99%
-  Incyte (NASDAQ:INCY) shares fell by 6.6% during mid-day trading on Monday, with significantly lower trading volume. Despite beating Q3 earnings and revenue estimates, analysts maintain a "Hold" consensus rating with an average price target of $99.07. Insider selling has occurred recently, while institutional investors hold a substantial portion of the company's stock.

**5. Invesco Ltd. Acquires 232,268 Shares of Incyte Corporation $INCY**
- Source: MarketBeat | 20251208T120836 | Somewhat-Bullish | Relevance: 99%
-  Invesco Ltd. increased its stake in Incyte Corporation (NASDAQ:INCY) by 7.3% during the second quarter, acquiring an additional 232,268 shares and bringing its total holdings to 3,401,018 shares valued at $231.6 million. The biopharmaceutical company has shown strong earnings, with a reported $2.26 EPS for the quarter, surpassing analyst estimates, and its stock has performed well, opening at $102.52 with a market cap of $20.13 billion.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $92 | $86 | +7% |
| 2025-12-08 | Wells Fargo | $116 | $97 | +20% |
| 2025-12-08 | Mizuho | $121 | $90 | +34% |
| 2025-11-24 | Barclays | $115 | $101 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Wells Fargo | main | Overweight |
| 2025-12-08 | Mizuho | up | Outperform |
| 2025-11-24 | Barclays | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.20M) |
| Sells | 13 ($23.25M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.8% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $23M sold (13 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +19%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.13 indicates undervaluation relative to growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (4 raises, avg +19%). Insider selling cluster ($23.2M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $18.7B |
| Beta | 0.81 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.13 |
| Forward P/E | 12.4 |
| Current P/E | 13.9 |
| YoY Growth | 12.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from -5.6% to -9.3% (-3.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 13.3pp (needs >4.0% for momentum thesis). AM_20 at -7.1% indicates price below own 20MA trend. Underperforming sector by 5.9pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.24x) but short-term weakness (below SMA20). MACD histogram bearish (-1.55), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -9.35% (CS: 3) | Weak |
| RSI_14 | 38.0 | Neutral |
| MACD Histogram | -1.55 | Bearish |
| vs SMA20 | 0.929x | Below |
| vs SMA50 | 0.990x | Below |
| vs SMA200 | 1.237x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $95.17
- **Stop Loss:** $88.17 (7.4% risk)
- **Target:** $109.17 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 71
- **Position Value:** $6,757.07
- **Portfolio %:** 6.76%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*